Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background

Multitargeted tyrosine kinase inhibitors (TKIs) are used to treat advanced non-small cell lung cancer (NSCLC). Their efficacy and safety have been studied in randomized controlled trials.

Aim

This meta-analysis aimed to summarize the most up-to-date evidence regarding the efficacy and adverse events of TKIs in NSCLC treatment.

Method

Randomized controlled trials were searched from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The intervention arm was the TKI-containing group, and the control arm was the TKI-free group. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival, and adverse events were extracted and synthesized. The last search was performed in April 2022. Two researchers independently screened articles, extracted data, and evaluated the quality of the included studies. The Cochrane risk-of-bias tool was used to assess the quality of each study. Random or fixed-effect models were used in statistical methods. I2 statistics were used to assess heterogeneity.

Results

Thirty-one studies (12,517 patients) were included. Compared to the control group, the TKI group had significantly higher ORR (relative risk RR 1.52, 95% confidence interval, CI [1.29, 1.80], P < 0.05), DCR (RR 1.34, 95%CI [1.19, 1.51], P < 0.05), and prolonged PFS (hazard ratio HR 0.67, 95%CI [0.59, 0.77], P < 0.05). The TKI group showed a higher rate of adverse events (RR 1.70, 95%CI [1.34, 2.16], P < 0.05) and grade 3–5 adverse events (RR 1.59, 95% CI [1.35, 1.88], P < 0.05).

Conclusion

TKIs could increase ORR and DCR and prolong PFS for advanced NSCLC. Adverse events should be closely monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87:211–9.

    Article  PubMed  Google Scholar 

  3. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 52017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:504–35.

    Article  PubMed  Google Scholar 

  4. Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12:3–20.

    Article  PubMed  CAS  Google Scholar 

  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  PubMed  CAS  Google Scholar 

  6. Hong M, Shi H, Wang N, et al. Dual effects of Chinese herbal medicines on angiogenesis in cancer and ischemic stroke treatments: Role of HIF-1 Network. Front Pharmacol. 2019;10:696.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. McLachlan J, Banerjee S. Pazopanib in ovarian cancer. Expert Rev Anticancer Ther. 2015;15:995–1005.

    Article  PubMed  CAS  Google Scholar 

  8. Wang C, Li L, Fu D, et al. Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition. Eur J Med Chem. 2019;176:135–48.

    Article  PubMed  CAS  Google Scholar 

  9. Huang L, Huang Z, Bai Z, et al. Development and strategies of VEGFR-2/KDR inhibitors. Fut Med Chem. 2012;4:1839–52.

    Article  CAS  Google Scholar 

  10. Kirtane K, Roth MY. Emerging therapies for radioactive iodine refractory thyroid cancer. Curr Treat Options Oncol. 2020;21:18.

    Article  PubMed  Google Scholar 

  11. Liang W, Wu X, Hong S, et al. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS ONE. 2014;9:e109757.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zhang Z, Zhao Y, Lu F, et al. Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Ann Transl Med. 2019;7:452.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Higgins JP, Altman DG, Gotzsche PC, Cochrane Statistical Methods G, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Duval S, Tweedie R. Trim and fill: a simple funnel plot-based method. Biometrics. 2000;56:455–63.

    Article  PubMed  CAS  Google Scholar 

  15. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007;25:4270–7.

    Article  PubMed  CAS  Google Scholar 

  16. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407–15.

    Article  PubMed  CAS  Google Scholar 

  17. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619–26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2010;28:49–55.

    Article  PubMed  CAS  Google Scholar 

  19. Socinski MA, Scappaticci FA, Samant M, et al. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010;5:354–60.

    Article  PubMed  Google Scholar 

  20. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:1835–42.

    Article  PubMed  CAS  Google Scholar 

  21. Wang Y, Wang L, Liu Y, et al. Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer. Chinese J Lung Cancer. 2011;14:239–44.

    Article  Google Scholar 

  22. Wang L, He Z, Yang S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. Transl Lung Cancer Res. 2019;8:575–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29:1067–74.

    Article  PubMed  Google Scholar 

  24. Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9:2621–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012;30:3084–92.

    Article  PubMed  CAS  Google Scholar 

  26. Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30:1114–21.

    Article  PubMed  CAS  Google Scholar 

  27. Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012;30:2829–36.

    Article  PubMed  CAS  Google Scholar 

  28. Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: north central cancer treatment group study N0528. J Thorac Oncol. 2013;8:79–88.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014;14:290.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gridelli C, Novello S, Zilembo N, et al. Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol. 2014;9:733–7.

    Article  PubMed  CAS  Google Scholar 

  31. Heist RS, Wang X, Hodgson L, et al. Alliance for Clinical Trials in O CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:214–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Yu Z, Cai X, Xu Z, et al. Apatinib plus chemotherapy as a second-line treatment in unresectable non-small cell lung carcinoma: a randomized, controlled. Multicenter Clin Trial Oncol. 2020;25:e1640–9.

    CAS  Google Scholar 

  33. Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014;50:706–12.

    Article  PubMed  CAS  Google Scholar 

  34. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.

    Article  PubMed  CAS  Google Scholar 

  35. O’Brien ME, Gaafar R, Hasan B, et al. Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010–018566-23, NCT01208064). Eur J Cancer. 2015;51:1511–28.

    Article  PubMed  CAS  Google Scholar 

  36. Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial: a phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015;10:1745–53.

    Article  PubMed  CAS  Google Scholar 

  37. Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73.

    Article  PubMed  Google Scholar 

  38. Baggstrom MQ, Socinski MA, Wang XF, et al. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (alliance). J Thorac Oncol. 2017;12:843–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Besse B, Mazieres J, Ribassin-Majed L, et al. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial. Ann Oncol. 2017;28:1078–83.

    Article  PubMed  CAS  Google Scholar 

  40. Kubota K, Yoshioka H, Oshita F, et al. Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2017;35:3662–70.

    Article  PubMed  CAS  Google Scholar 

  41. Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2018;36:1207–17.

    Article  PubMed  CAS  Google Scholar 

  42. Si XY, Wang HP, Zhang XT, et al. Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer. Zhonghua Nei Ke Za Zhi. 2018;57:830–4.

    PubMed  CAS  Google Scholar 

  43. Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–75.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lu S, Chen G, Sun Y, et al. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer: the FALUCA study. Lung Cancer. 2020;146:252–62.

    Article  PubMed  Google Scholar 

  46. Spagnuolo A, Palazzolo G, Sementa C, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opin Pharmacother. 2020;21:491–506.

    Article  PubMed  CAS  Google Scholar 

  47. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:650–6.

    Article  PubMed  CAS  Google Scholar 

  48. Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39:252–60.

    Article  PubMed  CAS  Google Scholar 

  49. Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

This research received no sources of funding.

Author information

Authors and Affiliations

  1. Department of Oncology, The First Hospital Affiliated to Army Medical University, Chongqing, China

    Keqian Zhang

  2. Department of Respiratory, The First Hospital Affiliated to Army Medical University, Chongqing, China

    Wenwei Wang & Lan Liang

  3. Department of Respiratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Ting Zhang

Authors
  1. Keqian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lan Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lan Liang.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, K., Wang, W., Zhang, T. et al. Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Int J Clin Pharm 44, 1232–1246 (2022). https://doi.org/10.1007/s11096-022-01465-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-022-01465-w

Keywords

Search

Navigation